Switching between two HER2-targeted regimens (HP+chemotherapy vs HPy+chemotherapy) after progression in advanced HER2-positive breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, natural-selection observational study plans to collect real-world data from about 600 patients with HER2-positive advanced or metastatic breast cancer across participating centers. Patients will be naturally allocated roughly 1:1 to either switch from HP + chemotherapy to HPy + chemotherapy or from HPy + chemotherapy to HP + chemotherapy, with treatment switching occurring at second-line after first-line failure. Predefined subgroups — including de novo stage IV patients, those with brain metastases, and patients without prior trastuzumab exposure — will be analyzed separately and not pooled into the overall analysis. Outcomes will include measures of efficacy and safety related to sequencing these targeted regimens in routine clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily signed the informed consent form with good compliance.
2. Female, aged 18 years or older.
3. Histologically confirmed diagnosis of HER2-positive advanced or metastatic breast cancer.
4. Metastatic lesions confirmed by MRI/contrast-enhanced CT, with at least one measurable lesion according to RECIST 1.1 criteria.
5. For patients previously treated with trastuzumab or tyrosine kinase inhibitors (TKIs) in the early-stage setting, recurrence must have occurred more than 1 year after the completion of prior treatment.
6. ECOG performance status score of 0-2.
7. Eligible patients meeting the treatment criteria specified in this study protocol may be included. This includes:Patients whose prior first-line and second-line treatments both align with the requirements of this protocol；Patients currently receiving second-line treatment whose prior first-line treatment aligns with the requirements of this protocol；The above populations may have previously received or not received trastuzumab and/or pertuzumab, small-molecule tyrosine kinase inhibitors (e.g., pyrotinib, etc.), and may include patients with brain metastases, among others.

   \-

Exclusion Criteria:

1. Known allergy to the drugs involved in this trial or their excipients.
2. Current or recent use of medications that may affect the metabolism or efficacy of pyrotinib or trastuzumab, such as strong CYP3A4 inhibitors (e.g., itraconazole, fluconazole, etc.), strong CYP3A4 inducers (e.g., rifampicin, efavirenz, etc.), or other drugs that may influence the plasma concentration of these two agents.
3. Pregnant or lactating women.
4. Major surgery within 4 weeks prior to the start of study drug administration, with incomplete recovery. Minor procedures such as tumor biopsy, thoracentesis, or venous catheter placement are permitted.
5. Presence of severe systemic diseases and/or uncontrolled infections.
6. Concurrent conditions considered by the investigator to pose a serious risk to patient safety or interfere with the patient's ability to complete the study (e.g., severe hypertension, diabetes, thyroid disorders, concurrent hepatitis B/C, or other active infections).
7. History of other malignancies.
8. Psychiatric illness, cognitive impairment, or inability to comply with the trial protocol and follow-up.
9. Other conditions deemed by the investigator to render the participant unsuitable for inclusion.

Where it's running

• Zhejiang Cancer Hospital
  Zhejiang, Hangzhou, China Recruiting

Study contacts

• Principal investigator: Hai Hu — Zhejiang Cancer Hospital
• Study coordinator: Ziwen Zhang
• Email: 16660496@qq.com
• Phone: +86 13588318799

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.